Trial Profile

A randomized, double-blind, placebo-controlled, multi-centre phase IIa study evaluating the safety and tolerability of IRL752 in patients with Parkinson's Disease Dementia.

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 26 Mar 2020

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Pirepemat (Primary)
Indications Dementia; Parkinson's disease
Focus Adverse reactions; Proof of concept
Sponsors Integrative Research Laboratories

Most Recent Events

12 Mar 2020 Results published in the Movement Disorders
23 Sep 2019 According to an Integrative Research Laboratories media release, results from this trial will be presented at the 2019 International Congress of Parkinson's Disease and Movement Disorders in Nice, France.
16 Nov 2018 Status changed from recruiting to completed.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com